Hospital
Banner - University Medical Center South Campus LLC
Banner - University Medical Center South Campus LLC was paid $82.41M by Medicaid between Jan 2018 and Dec 2024, across 355 billing codes. Its largest line is 99285, emergency room visit (most serious) — 26% of everything it billed.
33Billing provider infoBANNER - UNIVERSITY MEDICAL CENTER SOUTH CAMPUS LLC
TUCSON, AZ 85713
TUCSON, AZ 85713
33aNPI1558759498assigned 12/30/2014
33bProvider typeGeneral Acute Care Hospital
28Total paid$82.41M
24GClaims1,760,577
24DCodes billed355
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#4 of 78
Median peer was paid$12.21M
This provider vs. median6.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 276,304 | $13.08M | |
| 2019 | 259,214 | $14.13M | |
| 2020 | 208,481 | $11.64M | |
| 2021 | 255,654 | $11.85M | |
| 2022 | 273,746 | $11.39M | |
| 2023 | 275,122 | $11.68M | |
| 2024incomplete | 212,056 | $8.65M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 26% | 45,840 | 39,961 | $21.06M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 54,284 | 49,035 | $17.50M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 39,839 | 36,811 | $9.98M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 11% | 11,894 | 10,891 | $8.72M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.4% | 13,360 | 11,968 | $2.79M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 15,246 | 14,085 | $2.16M |
| 47562 | 2.6% | 444 | 421 | $2.13M | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.0% | 2,614 | 2,483 | $1.69M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.8% | 3,626 | 3,327 | $1.46M |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 1.7% | 933 | 828 | $1.42M |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 1.7% | 531 | 430 | $1.37M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.6% | 3,127 | 2,875 | $1.35M |
343 more codes
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.6% | 1,712 | $1.32M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 491 | $560K |
| G0378 | Hospital observation service, per hour | <1% | 16,958 | $558K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 874 | $534K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 450 | $411K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 676 | $408K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 637 | $383K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,538 | $380K |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | <1% | 150 | $342K |
| 93975 | <1% | 4,333 | $335K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,632 | $311K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,955 | $310K |
| 74183 | <1% | 1,656 | $303K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 1,418 | $272K |
| 72197 | <1% | 428 | $271K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 22,283 | $181K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,852 | $180K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 8,901 | $174K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 10,957 | $173K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,832 | $168K |
| 80053 | Comprehensive metabolic panel | <1% | 90,653 | $153K |
| 70498 | <1% | 333 | $124K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,043 | $123K |
| 70491 | <1% | 399 | $122K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,938 | $116K |
| 73130 | <1% | 5,269 | $114K | |
| 71250 | <1% | 1,674 | $98K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 6,078 | $95K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,377 | $94K |
| 76770 | <1% | 1,396 | $94K | |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | <1% | 82 | $91K |
| 77002 | <1% | 300 | $90K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 12,409 | $89K |
| J0490 | Injection, belimumab, 10 mg | <1% | 59 | $88K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 605 | $83K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,874 | $82K |
| 72141 | <1% | 328 | $76K | |
| 73630 | <1% | 6,124 | $69K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,577 | $60K |
| 76000 | <1% | 255 | $52K | |
| 71045 | Radiologic examination, chest; single view | <1% | 34,654 | $50K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 248 | $50K |
| 93017 | <1% | 881 | $49K | |
| 93970 | <1% | 923 | $46K | |
| 72100 | <1% | 1,376 | $46K | |
| 64721 | <1% | 41 | $45K | |
| 72131 | <1% | 542 | $45K | |
| 95819 | <1% | 217 | $45K | |
| 70486 | <1% | 2,014 | $41K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 14,916 | $39K |
| 93971 | <1% | 2,423 | $39K | |
| 73562 | <1% | 5,018 | $39K | |
| J3490 | Unclassified drugs | <1% | 73,213 | $38K |
| 73030 | <1% | 4,320 | $35K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 34 | $34K |
| C1755 | Catheter, intraspinal | <1% | 2,177 | $32K |
| 20553 | <1% | 318 | $31K | |
| 43235 | <1% | 62 | $28K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 50,666 | $27K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 434 | $26K |
| 73610 | <1% | 3,729 | $24K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 2,350 | $23K |
| 72128 | <1% | 132 | $23K | |
| C1781 | Mesh (implantable) | <1% | 152 | $21K |
| 74175 | <1% | 52 | $21K | |
| 76536 | <1% | 246 | $20K | |
| 20610 | <1% | 478 | $17K | |
| 73564 | <1% | 295 | $16K | |
| 73110 | <1% | 2,442 | $15K | |
| 70496 | <1% | 265 | $14K | |
| 93308 | <1% | 674 | $14K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 7,542 | $14K |
| 76830 | Ultrasound, transvaginal | <1% | 2,351 | $14K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 35,475 | $12K |
| 73080 | <1% | 1,578 | $12K | |
| 62323 | <1% | 227 | $11K | |
| 73502 | <1% | 1,727 | $11K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 495 | $11K |
| 10060 | <1% | 754 | $10K | |
| 72156 | <1% | 13 | $10K | |
| 12001 | <1% | 1,294 | $9K | |
| 20552 | <1% | 125 | $9K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 13,883 | $8K |
| 73700 | <1% | 87 | $8K | |
| 80320 | <1% | 14,741 | $8K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 13 | $8K |
| 73221 | <1% | 44 | $7K | |
| 70487 | <1% | 25 | $7K | |
| 76857 | <1% | 560 | $7K | |
| 93976 | <1% | 3,503 | $7K | |
| 70546 | <1% | 134 | $6K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15,134 | $6K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 31,890 | $6K |
| 74178 | <1% | 14 | $5K | |
| 74018 | <1% | 1,272 | $4K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 7,215 | $4K |
| 72040 | <1% | 248 | $4K | |
| 72072 | <1% | 77 | $4K | |
| 91010 | <1% | 12 | $4K | |
| 72146 | <1% | 31 | $4K | |
| 72110 | <1% | 59 | $3K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 16,734 | $3K |
| 95812 | <1% | 14 | $3K | |
| 73590 | <1% | 2,789 | $3K | |
| 97162 | <1% | 311 | $3K | |
| 84484 | <1% | 43,671 | $3K | |
| C1769 | Guide wire | <1% | 500 | $2K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,166 | $2K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 94,132 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,619 | $2K |
| 83605 | <1% | 21,050 | $2K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,869 | $2K |
| 73552 | <1% | 623 | $2K | |
| 96376 | <1% | 10,519 | $2K | |
| 87631 | <1% | 2,037 | $2K | |
| 82805 | <1% | 7,629 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,240 | $2K |
| 73140 | <1% | 780 | $2K | |
| 73090 | <1% | 1,982 | $2K | |
| 73620 | <1% | 135 | $2K | |
| 87186 | <1% | 6,194 | $1K | |
| 76870 | <1% | 784 | $1K | |
| 82947 | <1% | 35,199 | $1K | |
| 81025 | <1% | 8,417 | $1K | |
| 76801 | <1% | 1,488 | $1K | |
| 72170 | <1% | 1,229 | $1K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,696 | $1K |
| 97161 | <1% | 432 | $1K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 20 | $1K |
| 12002 | <1% | 670 | $975.93 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,929 | $868.34 |
| 76775 | <1% | 32 | $857.58 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,946 | $827.99 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 461 | $822.40 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 14,002 | $784.06 |
| 84703 | <1% | 19,621 | $700.11 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 7,097 | $633.48 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,036 | $630.45 |
| 12011 | <1% | 398 | $628.38 | |
| 83690 | <1% | 29,613 | $621.06 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 3,203 | $602.57 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 17,430 | $594.02 |
| 90715 | <1% | 4,465 | $593.96 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 16,810 | $565.80 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 18,325 | $560.60 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 922 | $474.87 |
| 81001 | <1% | 29,398 | $447.90 | |
| 96415 | <1% | 2,038 | $413.00 | |
| 36430 | <1% | 39 | $398.41 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 551 | $386.96 |
| 84702 | <1% | 6,821 | $366.82 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 31,294 | $366.51 |
| 83735 | <1% | 16,519 | $356.34 | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 59 | $345.46 |
| 87088 | <1% | 12,039 | $334.45 | |
| 83880 | <1% | 7,286 | $323.06 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 5,317 | $304.24 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 14,842 | $285.36 |
| 87040 | <1% | 9,526 | $273.29 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 50,757 | $268.19 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,007 | $268.06 |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 17 | $244.77 |
| 73120 | <1% | 59 | $240.30 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 34 | $222.87 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 491 | $222.20 |
| 73060 | <1% | 800 | $202.25 | |
| 96367 | <1% | 2,915 | $201.54 | |
| 73070 | <1% | 48 | $192.80 | |
| J2704 | Injection, propofol, 10 mg | <1% | 15,380 | $190.76 |
| 82550 | <1% | 4,142 | $185.84 | |
| 97014 | <1% | 602 | $184.40 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,163 | $180.09 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 660 | $176.72 |
| 85610 | <1% | 12,823 | $163.93 | |
| 87077 | <1% | 7,563 | $158.03 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 9,196 | $153.23 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 12,180 | $150.51 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 5,984 | $149.88 |
| 76882 | <1% | 14 | $135.02 | |
| 81003 | <1% | 12,986 | $124.95 | |
| 80329 | <1% | 1,939 | $121.81 | |
| 85027 | <1% | 9,759 | $119.37 | |
| 84439 | <1% | 2,882 | $118.41 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 2,820 | $112.52 |
| 86703 | <1% | 2,232 | $106.84 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 710 | $101.34 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,936 | $97.39 |
| 87210 | <1% | 3,577 | $95.14 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 12,816 | $95.07 |
| 85379 | <1% | 2,782 | $89.71 | |
| 84100 | <1% | 10,059 | $83.08 | |
| 27096 | <1% | 23 | $81.19 | |
| 80061 | Lipid panel | <1% | 1,912 | $74.40 |
| 87081 | <1% | 33 | $72.37 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 4,293 | $71.52 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,982 | $71.33 |
| 85730 | <1% | 3,978 | $69.85 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,788 | $68.84 |
| 76377 | <1% | 1,082 | $64.39 | |
| 86850 | <1% | 3,985 | $53.35 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,374 | $52.95 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,791 | $46.52 |
| 82140 | <1% | 1,727 | $44.49 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 286 | $42.79 |
| 86140 | <1% | 5,364 | $42.02 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 6,020 | $41.40 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,393 | $39.77 |
| 84145 | <1% | 1,108 | $39.63 | |
| 87205 | <1% | 1,604 | $39.23 | |
| 86780 | <1% | 299 | $37.62 | |
| A9270 | Non-covered item or service | <1% | 78,994 | $36.35 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 2,239 | $36.00 |
| 80164 | <1% | 54 | $34.30 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,939 | $31.66 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 826 | $31.03 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,887 | $30.61 |
| 86592 | <1% | 1,014 | $28.94 | |
| 82330 | <1% | 1,255 | $27.42 | |
| 82010 | <1% | 1,551 | $26.49 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 12,701 | $25.54 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 11,675 | $24.66 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 4,238 | $23.86 |
| 85055 | <1% | 1,328 | $22.87 | |
| 86901 | <1% | 4,458 | $18.75 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 273 | $18.14 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,642 | $18.02 |
| 96368 | <1% | 815 | $17.96 | |
| 84132 | <1% | 1,623 | $17.20 | |
| J1815 | Injection, insulin, per 5 units | <1% | 6,635 | $17.05 |
| 86900 | <1% | 4,445 | $16.48 | |
| 87070 | <1% | 1,106 | $16.13 | |
| 73560 | <1% | 15 | $15.96 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,594 | $14.19 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 825 | $13.96 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,823 | $13.07 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,250 | $12.61 |
| 80076 | <1% | 75 | $12.23 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,762 | $12.10 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 2,328 | $9.70 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,879 | $8.95 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,915 | $7.19 |
| J0456 | Injection, azithromycin, 500 mg | <1% | 262 | $7.09 |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 5,269 | $5.85 |
| 84295 | <1% | 1,129 | $4.79 | |
| 82270 | <1% | 561 | $3.98 | |
| 85652 | <1% | 2,240 | $1.93 | |
| 88304 | 0% | 1,667 | $0.00 | |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 1,509 | $0.00 |
| 90686 | 0% | 60 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 747 | $0.00 |
| 80349 | 0% | 12 | $0.00 | |
| 88342 | 0% | 472 | $0.00 | |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 296 | $0.00 |
| 86769 | 0% | 139 | $0.00 | |
| 88307 | 0% | 145 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 1,056 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 30 | $0.00 |
| 73600 | 0% | 22 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 1,251 | $0.00 |
| J1836 | Injection, metronidazole, 10 mg | 0% | 83 | $0.00 |
| 36416 | 0% | 188 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 2,081 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 15 | $0.00 |
| 97166 | 0% | 83 | $0.00 | |
| 87206 | 0% | 16 | $0.00 | |
| 86635 | 0% | 240 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 148 | $0.00 |
| 87430 | 0% | 183 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 286 | $0.00 |
| 94760 | 0% | 638 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 57 | $0.00 |
| 70548 | 0% | 55 | $0.00 | |
| 86803 | 0% | 130 | $0.00 | |
| 85018 | 0% | 135 | $0.00 | |
| 87147 | 0% | 337 | $0.00 | |
| 71101 | 0% | 59 | $0.00 | |
| A9573 | Injection, gadopiclenol, 1 ml | 0% | 15 | $0.00 |
| C9399 | Unclassified drugs or biologicals | 0% | 108 | $0.00 |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | 0% | 45 | $0.00 |
| 87340 | 0% | 142 | $0.00 | |
| 80177 | 0% | 12 | $0.00 | |
| J3535 | Drug administered through a metered dose inhaler | 0% | 17 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 46 | $0.00 |
| J0571 | Buprenorphine, oral, 1 mg | 0% | 50 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 13 | $0.00 |
| 64494 | 0% | 39 | $0.00 | |
| 90632 | 0% | 54 | $0.00 | |
| 82728 | 0% | 42 | $0.00 | |
| 82607 | 0% | 12 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 43 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 329 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 19 | $0.00 |
| 84478 | 0% | 22 | $0.00 | |
| 94762 | 0% | 18 | $0.00 | |
| 64493 | 0% | 42 | $0.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 13 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 96 | $0.00 |
| 87506 | 0% | 20 | $0.00 | |
| 36415 | Collection of venous blood by venipuncture | 0% | 35 | $0.00 |
| 83615 | 0% | 12 | $0.00 | |
| 87075 | 0% | 382 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 358 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 1,246 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 147 | $0.00 |
| 85007 | 0% | 616 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 167 | $0.00 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 1,037 | $0.00 |
| 84466 | 0% | 71 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 694 | $0.00 |
| 95957 | 0% | 531 | $0.00 | |
| 93325 | 0% | 14 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 124 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 950 | $0.00 |
| 97163 | 0% | 140 | $0.00 | |
| Q9956 | Injection, octafluoropropane microspheres, per ml | 0% | 36 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 53 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 207 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 1,171 | $0.00 |
| 73100 | 0% | 30 | $0.00 | |
| 84460 | 0% | 73 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 93 | $0.00 |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | 0% | 20 | $0.00 |
| 51702 | 0% | 62 | $0.00 | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 0% | 29 | $0.00 |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 185 | $0.00 |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | 0% | 44 | $0.00 |
| 31500 | 0% | 37 | $0.00 | |
| 99152 | 0% | 30 | $0.00 | |
| P9016 | Red blood cells, leukocytes reduced, each unit | 0% | 54 | $0.00 |
| 29125 | 0% | 16 | $0.00 | |
| 87149 | 0% | 55 | $0.00 | |
| 83540 | 0% | 86 | $0.00 | |
| 93041 | 0% | 42 | $0.00 | |
| 86923 | 0% | 26 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 185 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 19 | $0.00 |
| 85014 | 0% | 15 | $0.00 | |
| 80074 | 0% | 14 | $0.00 | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 0% | 13 | $0.00 |
| 88302 | 0% | 16 | $0.00 | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 22 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 40 | $0.00 |
| 97012 | 0% | 36 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPOST, DAN (CEO)
Parent organizationBANNER HEALTH
| Provider | Location | Paid |
|---|---|---|
| Banner - University Medical Center Tucson Campus LLC | Tucson, AZ | $194.42M |
| Banner - University Medical Center Phoenix | Phoenix, AZ | $140.85M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.